Allist released its 2026 interim report on August 20, 2026. Total operating revenue was 3.32 billion yuan, net profit attributable to the parent company was 1.541 billion yuan, and net cash inflow from operating activities was 1.445 billion yuan. The company's latest asset-liability ratio was 10.38 percent, up 0.56 percentage points from the previous quarter. The latest gross margin was 94.85 percent, down 0.06 percentage points from the previous quarter and down 2.01 percentage points from the same period last year. The latest return on equity was 18.21 percent, and diluted earnings per share was 3.42 yuan. The company's latest total asset turnover was 0.38 times, and the latest inventory turnover was 2.16 times. The number of shareholders was 21,000, and the top ten shareholders held 266 million shares, accounting for 59.00 percent of the total share capital.
Shanghai Allist Pharmaceuticals Co. Ltd. AInterim report shows strong net profit of 1.541 billion yuan on revenue of 3.32 billion yuan.